Chlamydia trachomatis Antibody, IgA

The Chlamydia trachomatis IgA antibody test (Anti–Chlamydia trachomatis IgA serology) supports the diagnosis of acute or reactivated C. trachomatis infection and can assist with staging in the clinical context. It is used to inform initiation of antimicrobial therapy and to monitor response to antibiotic treatment over time. In pregnancy, when inflammation of the genital or urinary tract is present, C. trachomatis IgA may be used to gauge the risk of perinatal transmission. Serology is an adjunct and does not replace site-specific direct detection methods.

Chlamydia trachomatis is an obligate intracellular pathogen with a two-stage developmental cycle. Extracellular elementary bodies, which are relatively antibiotic-insensitive, attach to and enter host cells and differentiate into intracellular reticulate bodies that replicate and are antibiotic-sensitive. The organism targets columnar epithelium of the urethra, endocervix, rectum, pharynx, and conjunctiva, and in infants can involve the respiratory tract. Transmission occurs via mucosal contact—most often sexual—and during passage through the birth canal. In women, infection commonly manifests as cervicitis and may ascend to endometritis and salpingitis, with potential sequelae including tubal occlusion, infertility, ectopic pregnancy, and, less frequently, perihepatitis. In men, presentations include nongonococcal urethritis, epididymitis, and prostatitis. A substantial proportion of infections—up to half—are asymptomatic or only mildly symptomatic, facilitating unrecognized transmission. The humoral immune response includes IgM, IgA, and IgG, which tend to align with different phases of infection. Serum IgA reflects an active mucosal response; it usually appears 10–15 days after primary infection, declines with time, and may persist in chronic or recurrent disease. Serologic testing complements, but does not substitute for, direct detection at the site of infection when a definitive, site-specific diagnosis is required.